WallStSmart

Cps Technologies (CPSH)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 694% more annual revenue ($258.90M vs $32.60M). CPSH leads profitability with a 1.3% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

CPSH

Avoid

32

out of 100

Grade: F

Growth: 6.0Profit: 3.5Value: 3.7Quality: 7.8
Piotroski: 5/9

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CPSHOvervalued (-5.2%)

Margin of Safety

-5.2%

Fair Value

$4.59

Current Price

$4.93

$0.34 premium

UndervaluedFair: $4.59Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CPSH2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
38.3%10/10

Revenue surging 38.3% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

CPSH4 concerns · Avg: 2.8/10
Market CapQuality
$95.08M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.1%3/10

ROE of 2.1% — below average capital efficiency

Profit MarginProfitability
1.3%3/10

1.3% margin — thin

P/E RatioValuation
176.0x2/10

Premium valuation, high expectations priced in

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CPSH

The strongest argument for CPSH centers on Revenue Growth, Debt/Equity. Revenue growth of 38.3% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : CPSH

The primary concerns for CPSH are Market Cap, Return on Equity, Profit Margin. A P/E of 176.0x leaves little room for execution misses. Thin 1.3% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 32/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cps Technologies

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

CPS Technologies Corporation produces and sells advanced materials solutions for the transportation, automotive, energy, computing / internet, telecommunications, aerospace, defense, and oil and gas markets. The company is headquartered in Norton, Massachusetts.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?